Interferons (IFNs) play an important role in the innate and adaptive immune responses against viral infections \[[@CR20]\]. Type III IFNs (IFN-λs) were first identified in 2003 and are encoded by 1--3 functional genes in most mammalian species \[[@CR22]\]. Humans and chickens have three IFN-λs as follows: IFN-λ1 (IL-29), IFN-λ2 (IL-28A), and IFN-λ3 \[[@CR12]\]. Mice have genes only for IFN-λ2 and IFN-λ3 \[[@CR7]\]. Two members, IFN-λ1 (IL-29) and IFN-λ3 (IL-28B), have been recently identified in swine \[[@CR21]\].

Distinct from the receptors for type I and II IFNs, type III IFN exerts its action through a heterodimeric cellular receptor that is composed of IL28-Rα, a type III IFN specific subunit, and IL10-Rβ, a subunit shared by other IL-10-related cytokines \[[@CR18]\]. As IFN-λs bind to these unique receptors, they activate Janus kinase I, together with signaling transducers and activators of transcription (STAT) factors 1 and 2, resulting in the formation of the IFN-stimulated gene factor 3 (ISGF3) complexes \[[@CR14]\]. This then induces the transcription of IFN-stimulated genes (ISGs), such as 2′,5′-oligoadenylate synthetase (2′,5′-OAS) and MxA genes \[[@CR14]\]. IFN-λs share a number of common biological characteristics with type I IFN, such as antiviral, antiproliferative, and antitumor activities \[[@CR3], [@CR8], [@CR9], [@CR17]\]. The expression of IFN-λs can be induced by viral infection or treatment with poly (I:C) as well as lipopolysaccharide (LPS) \[[@CR17]\]. Previous studies have demonstrated that IFN-λs can induce protection against several viruses in cell culture, such as West Nile virus \[[@CR16]\], influenza A virus \[[@CR10]\], porcine reproductive and respiratory syndrome virus \[[@CR15]\], and foot-and-mouth disease virus \[[@CR5]\].

Porcine epidemic diarrhea virus (PEDV) is a member of the family *Coronaviridae*, and is an important etiological agent of lethal watery diarrhea in piglets, resulting in large economic losses in many Asian and European countries \[[@CR23], [@CR24]\]. Previous research has demonstrated that PEDV infection suppresses the production of IFN-β, and viral papain-like protease 2 has been identified as a type I interferon antagonist \[[@CR4], [@CR6], [@CR24], [@CR25]\]. In this study, poIFN-λ3 was cloned and expressed in *Escherichia coli* using the pET-32a vector. In addition, the molecular characterization of poIFN-λ3 was analyzed, and the antiviral activity of poIFN-λ3 against PEDV was evaluated. Furthermore, a real-time quantitative PCR assay was used to quantify the expression levels of ISGs, OAS1, and M*x*1 induced by poIFN-λ3 to elucidate the mechanism of poIFN-λ3 antiviral efficacy.

Based on our experiments, poIFN-λ3 gene was amplified using RT-PCR from ST cells stimulated with poly (I:C) and subcloned into pET-32a expression vector, transformed into host bacteria *Rosetta gami* B. The recombinant poIFN-λ3 was expressed by IPTG induction and existed in inclusion bodies (Fig. [1](#Fig1){ref-type="fig"}). PoIFN-λ3 was purified by Ni--NTA affinity chromatography using an ÄKTA purifier FPLC (GE Healthcare). After refolding, the eluted protein was dialyzed against phosphate-buffered saline (PBS) and filtered through a 0.22-μm filter and stored at −80 °C for further use. The purified poIFN-λ3 protein was tested via the CPE inhibition assay using Vesicular stomatitis virus (VSV)/MDBK systems. The results demonstrated that poIFN-λ3 possessed an anti-VSV activity.Fig. 1Cloning, expression, and purification of recombinant poIFN-λ3 in *R. gami* B. **a** Molecular cloning of poIFN-λ3. **b** SDS-PAGE analysis of samples.*M*, molecular weight marker; *lane 1* the supernatant of bacterial cells harboring pET-poIFN-λ3 without IPTG induced; *lane 2* the precipitation of bacterial cells harboring pET-poIFN-λ3 without IPTG induced; *lane 3* the supernatant of bacterial cells harboring pET-poIFN-λ3 with 0.4 mM IPTG induced for 16 h at 20 °C; *lane 4* the precipitation of bacterial cells harboring pET-poIFN-λ3 with 0.4 mM IPTG induced for 16 h at 20 °C.**c** Western blot using an anti-His antibody.*M*, molecular weight marker; *lane 1* *R. gami* B extract transformed by pET-32a (+) (negative control); *lane 2* *R. gami* B extract transformed by pET-poIFN-λ3

The sequencing results demonstrated that the full-length cDNA of poIFN-λ3 contains 588 bp and encodes 196 amino acid residues. The identified poIFN-λ3 sequence encodes a protein of MW = 21486.09 with a p*I* of 9.27 (<http://web.expasy.org/compute_pi/>). Moreover, a predicted signal peptide is located between amino acids 1 and 23 \[[@CR2]\] and a putative N-linked glycosylation sequence was between amino acids 71 and 74 (<http://www.cbs.dtu.dk/services/NetNGlyc/>) (Fig. [2](#Fig2){ref-type="fig"}a, c).Fig. 2Amino acid sequences analysis, phylogenetic tree, and prediction of a signal peptide for poIFN-λ3. **a** Alignment of amino acid sequences for porcine, *B. taurus*, *O. aries*, *T. belangeri*, *Pan troglodytes*, *Equus caballus*, *Mus musculus,* *Gallus silurana*, and *Homo sapiens* IFN-λ3. The*numbers* indicate the amino acid position. Predicted signal peptide: amino acids 1--23 (*boxed in blue*). Putative N-glycosylation site: amino acids 71--74 (*boxed in red*). **b** A phylogenetic tree of the nine identified or predicted IFN-λ3 from different species. The uprooted tree was built using the neighbor-joining method based on the alignment of IFN-λ3 amino acid sequences. The *scale bar* is 0.1. **c** The signal peptide of poIFN-λ3 was predicted by SignalP3.0 Server.*C*,*S*, and*Y scores*indicate cleavage sites, 'signal peptide-ness,' and combined cleavage site predictions, respectively (Color figure online)

To gain insight into the poIFN-λ3, BLASTN was performed using the IFN-λ3 sequences from nine species in GenBank. The nucleic acid sequence analysis revealed that poIFN-λ3 had a high similarity to *Ovis aries* IFN-λ3 (GenBank No. XM_004015683; 87.4 %), *Bos taurus* IFN-λ3 (GenBank No.XM_003585012; 85.5 %), *Tupaia belangeri* IFN-λ3 (GenBank No. JX185489; 80.9 %), *Pan troglodytes* IFN-λ3 (GenBank No. XM_001135462; 80.9 %), *Homo sapiens* IFN-λ3 (GenBank No. NM_172139; 78.9 %), and *Equus caballus* IFN-λ3 (GenBank No. NM_172139; 78.1 %), respectively. The amino acid sequence analysis results showed that poIFN-λ3 also has a high identity to *O. aries* (78.1 %), *B. taurus* (76.0 %), *T. belangeri* (71.3 %), *E. caballus* (69.9 %), and *H. sapiens* (69.9 %) IFN-λ3. The phylogenetic tree was constructed using the MEGA program and a neighbor-joining analysis method based on the DNA sequences. The phylogenetic analysis indicated that the poIFN-λ3 is located on the same branch as the *B. taurus* and *O. aries* genes (Fig. [2](#Fig2){ref-type="fig"}b).

For the studies of antiviral activity, PEDV strain CV777 was used as a model virus to evaluate the antiviral activity of poIFN-λ3. The virus was propagated and titrated in Vero E6 cells. Recombinant poIFN-λ3 were expressed, purified, and stored at −80 °C in our laboratory. For the anti-PEDV effects, Vero E6 cells were incubated with poIFN-λ3 either 24 h prior to PEDV infection, simultaneously with PEDV infection, or 12 h after PEDV infection. The productive PEDV infection was determined at day 2 postinfection. The viral titer was determined using TCID~50~. Also, the amounts of viral RNAs were detected by a real-time quantitative RT-PCR \[[@CR13]\]. The results indicated that poIFN-λ3 could effectively inhibit the PEDV replication under three different treatment conditions. The highest inhibition of PEDV was observed in Vero E6 cell cultures pretreated with poIFN-λ3 (prior to PEDV infection) (Fig. [3](#Fig3){ref-type="fig"}a). To evaluate the dose-dependent effect of poIFN-λ3 on PEDV infection, Vero E6 cells were pretreated with poIFN-λ3 (10, 100, or 1000 ng/mL doses of poIFN-λ3) for 24 h prior to PEDV infection. The cells were then infected with PEDV for 2 h, washed, and replenished with fresh medium containing the indicated poIFN-λ3. Then, after 48 h infection, the cells were submitted to three freeze--thaw cycles and titrated by TCID~50~. Treatment with 10, 100, or 1000 ng/mL doses of poIFN-λ3 could protect Vero E6 cells from PEDV infection (Fig. [3](#Fig3){ref-type="fig"}c). As shown in Fig. [3](#Fig3){ref-type="fig"}b, treatment of Vero E6 cells with poIFN-λ3 (100 ng/mL) could inhibit the replication of PEDV at 12, 24, 36, and 48 h after infection. Therefore, poIFN-λ3 could significantly inhibit PEDV propagation in a dose- and time-dependent manner. In addition, the results demonstrated that the poIFN-λ3 can effectively reduce the amounts of PEDV RNAs in samples poIFN-λ3 prior to PEDV infection. And, accompanying dose of poIFN-λ3 increased (from 10 to 1000 ng/ml) and PEDV RNAs were reduced (Fig. [3](#Fig3){ref-type="fig"}d, e). These results were consistent with the TCID~50~ assay.Fig. 3Effect of poIFN-λ3 on PEDV infection of Vero E6 cells. **a** Effect of poIFN-λ3 on PEDV infection and replication under three different conditions. Vero E6 cells were pretreated with poIFN-λ3 (100 ng/mL) for 24 h, and then infected with PEDV CV777 strain (Before) or coincubated with poIFN-λ3 (100 ng/mL) and PEDV CV777 strain at the same time (during), or 12 h after PEDV infection, Vero E6 cells were treated with 100 ng/mL poIFN-λ3 (After). **b** Time-dependent effect of poIFN-λ3 on PEDV infection. Vero E6 cells were infected with PEDV CV777 strain for 12 h and then treated with poIFN-λ3 at a concentration of 100 ng/mL. The PEDV titer in the supernatant at the indicated time point was titrated by TCID~50~. **c** Dose-dependent effect of poIFN-λ3 on PEDV infection. Vero E6 cells were infected with PEDV CV777 strain for 12 h and then treated with poIFN-λ3 at the indicated concentrations. The PEDV titer in the supernatant was analyzed at 48 h postinfection. **d**, **e** Real-time quantitative RT-PCR detection of PEDV-N mRNA transcripts relative to β-actin transcripts in the same sample. The mean of three repeat experiments performed in triplicate is shown and *error bars* represent the SD. **d** is under three different conditions and **e** is at different doses of poIFN-λ3

To better illustrate the mechanism of antiviral activity elicited by poIFN-λ3 in Vero E6 cells, for the analysis of gene expression, we focused on ISGs (including ISG15, Mx1, and OAS1 and the primers of these three genes are listed in Table [1](#Tab1){ref-type="table"}) in which the expression has been shown to be up regulated by type III IFN in other species \[[@CR1]\]. Vero E6 cells were treated with 100 ng/mL poIFN-λ3 and cell samples were collected 24 h posttreatment. Untreated Vero E6 cells were also collected as a calibrator to evaluate the mRNA levels of the chosen ISGs. GAPDH was used as a housekeeping gene for sample normalization. Total RNA was extracted from these Vero E6 cells, and qRT-PCR was performed using LightCycler^®^ 96 SW 1.1 system and a SYBR Green I PCR master mix (Baoshengwu, Dalian, China). The samples were analyzed in triplicate. Levels of mRNA were calculated using the $\documentclass[12pt]{minimal}
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                \begin{document}$$2^{{ - \Delta \Delta C_{t} }}$$\end{document}$ method, which expresses mRNA in treated cells relative to untreated cells after normalizing to GAPDH. As shown in Fig. [4](#Fig4){ref-type="fig"}, all tested IFNs induced a significant increase in the mRNA expression of the antiviral genes ISG15, OAS1, and Mx1, all of which have well-known antiviral properties and may affect PEDV replication.Table 1Primer sequences used in this studyGenesPrimer namesSequence (5′--3′)Size (bp)*OAS1*OAS1-FGGTTGTCTTCCTCAGTCCTC136OAS1-RAGCCTGGACCTCAAACTTCA*Mx1*Mx1-FGCAGCCAGTACGAGGAGAAG153Mx1-RCTCCTGACAGTGCCTCCAAC*ISG15*ISG15-FGGGCAACGAGTTCCAGGT193ISG15-RCACCACCAGCAGGACCGT*GAPDH*GAPDH-FAGCCAAAAGGGTCATCATCT180GAPDH-RATGAGTCCTTCCACGATACC*N*N-FCGCAAAGACTGAACCCACTAATTTN-RTTGCCTCTGTTGTTACTTG GAGAT198β-actinActin-FGGACTTCGAGCAGGAGATGGActin-RAGGAAGGAGGGCTGGAAGAG138 Fig. 4Expressions of OAS1, Mx1, and ISG15 induced by poIFN-λ3. The levels of OAS1, Mx1, and ISG15mRNA were measured by quantitative PCR, and the results were normalized by the GAPDH levels of each sample. Values represent the mean ± SD of three independent tests. *P* \< 0.01 compared with the untreated Vero E6 cells

PEDV replicates in the small intestine epithelial cells, resulting in an acute and highly contagious enteric disease \[[@CR11]\]. Recently, studies have proved the importance of IFN-λ for restricting viral infection in the intestinal epithelium \[[@CR19]\]. IFN-λ plays a potent antiviral state by regulating the expression of IFN-stimulated genes (ISGs). Therefore, IFN-λ is important to efficiently restrict enteric coronavirus infections in the intestinal epithelial surface, including PEDV, TGEV, and possibly PDCoV infections. Correspondingly, these viruses may influence the host IFN-λ response. So, it is beneficial to understand the pathogenic mechanisms of porcine enteric coronaviruses and host responses to such infections \[[@CR26]\].

In summary, poIFN-λ3 was successfully cloned, expressed, and possesses antiviral activity against PEDV in a dose- and time-dependent manner in vitro, suggesting that poIFN-λ3 may be a broad-spectrum antiviral agent. The treatment of Vero E6 cells with poIFN-λ3 induced the expressions of ISG15, OAS1, and Mx1. Moreover, this study provides a foundation to utilize type III IFNs as useful antiviral agents against swine infectious diseases.
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